@article{b399a47a607d4aaf9456a3db25fb8261,
title = "Commentary: High-dose induction chemoradiation for lung cancer: The past is prologue",
author = "Nasser Altorki and Brendon Stiles",
note = "Funding Information: Disclosures: Dr Altorki receives clinical trial support from Astra-Zeneca LLC. Dr Stiles has speaker and advisory board roles for AstraZeneca, has a speaker role for Medtronic and WebMD, has an advisory board role for the Lung Cancer Research Foundation, reports spouse's ownership of Pfizer stock, and reports spouse's receipt of a salary from and ownership of stock in Pharmaceutical Product Development.",
year = "2020",
month = nov,
doi = "10.1016/j.jtcvs.2019.09.010",
language = "English (US)",
volume = "160",
pages = "1346--1347",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "5",
}